Project Grant R01HL173271
Award Date
9/1/24
Completion Date
6/30/28
Dollars Obligated
$1.4M
Federal Agency
National Heart Lung and Blood Institute
Awardee
Yale Univ (FL6GV84CKN57)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
New Haven, CT 06510, USA
Similar Awards
This $2,960,139 Project Grant, awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) on September 5, 2024, supports a comprehensive research project focused on assessing sudden cardiac death (SCD) risk and providing mechanistic insights in patients with arrhythmic mitral valve prolapse (MVP). The project aims to: 1) Perform deep phenotyping of MVP patients to understand characteristics and mechanisms associated with ventricular arrhythmias;...
This Project Grant award, totaling $1,862,169.00 and funded by the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 Cardiovascular Diseases Research, supports a comprehensive research initiative to investigate the mechanism of myocardial fibrosis induced by mitral valve prolapse (MVP). The research project, led by The General Hospital Corporation (doing business as Massachusetts General Hospital), aims to elucidate the link between altered mechanical forces caused by MVP and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research provides $2,940,607 to IHC Health Services Inc. (Intermountain Healthcare) to enhance clinical identification of individuals at risk of moderate to severe mitral valve prolapse (MVP) and associated adverse health outcomes. The project aims to: 1) describe the history of MVP, related cardiac morbidities, and contributing conditions using Intermountain...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $2,508,095 to Yale University to conduct research on the role of aberrant cell-extracellular matrix interactions in the development of thoracic aortic disease. The 5-year project aims to elucidate the molecular, cellular, and biomechanical mechanisms underlying thoracic aortopathy, with the goal of identifying new treatment targets. The research will utilize...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $172,800 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to The Trustees of Columbia University in the City of New York, Health Sciences Division. The grant, awarded on July 20, 2025, will fund research to predict the hemodynamic response to mitral valve interventions using pressure-volume analysis. The research aims to: 1) identify new echocardiographic measures of left ventricular systolic function in...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $321,848 to The Trustees of the University of Pennsylvania to conduct research on the role of hemodynamic forces and transcription factors KLF2 and KLF4 in regulating myxomatous valve disease pathogenesis. The research aims to characterize the impact of hemodynamic forces on valve homeostasis, identify specific targets of valve...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $298,368 to Link Medical LLC to develop a novel device for treating mitral valve regurgitation. The funded project aims to optimize the device design and procedure through bench testing, followed by in vivo feasibility studies. The goal is to create a simpler, more robust, and more effective solution than existing technologies for...
This $834,249 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a comparative study of clinical outcomes, patient experiences, and mechanistic insights between transcatheter and surgical treatment of degenerative mitral regurgitation (DMR). The study aims to provide long-term data on clinical effectiveness, safety, and patient-reported outcomes to inform treatment selection and guide patient care. It will also utilize...
This federal Project Grant award, provided by the National Heart Lung and Blood Institute under CFDA 93.837 - Cardiovascular Diseases Research, supports a $2,703,199 research project at Vanderbilt University Medical Center to investigate the role of Tie2 signaling in aortic valve remodeling. The 4-year project aims to delineate the unique roles of Tie2 signaling in heart valve remodeling, define the Tie2-PI3K/AKT-FOXO1 signaling pathway during semilunar valve remodeling, and identify...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $540,856 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF) on Dec 15, 2024. The goal of this 4-year project is to identify transcriptional regulators that control endocardial-specific gene expression and valve development, as well as understand the regulation and function of the SLC16A2 gene during heart injury and regeneration. The...